305 related articles for article (PubMed ID: 35726525)
21. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Alfayez M; Konopleva M; Pemmaraju N
Expert Opin Biol Ther; 2020 Feb; 20(2):115-123. PubMed ID: 31801379
[No Abstract] [Full Text] [Related]
22. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.
Kerr D; Sokol L
Expert Opin Investig Drugs; 2018 Sep; 27(9):733-739. PubMed ID: 30118336
[TBL] [Abstract][Full Text] [Related]
23. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
[TBL] [Abstract][Full Text] [Related]
25. Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.
Cangini D; Silimbani P; Cafaro A; Giannini MB; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):467-477. PubMed ID: 32955827
[TBL] [Abstract][Full Text] [Related]
26. Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Ashok Kumar P; Ombada M; Pemmasani G; Tambe A; Banki K; Gentile T
J Investig Med High Impact Case Rep; 2022; 10():23247096221127114. PubMed ID: 36341907
[TBL] [Abstract][Full Text] [Related]
27. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.
Sun W; Liu H; Kim Y; Karras N; Pawlowska A; Toomey D; Kyono W; Gaynon P; Rosenthal J; Stein A
J Hematol Oncol; 2018 May; 11(1):61. PubMed ID: 29720227
[TBL] [Abstract][Full Text] [Related]
28. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.
Pemmaraju N; Wilson NR; Senapati J; Economides MP; Guzman ML; Neelapu SS; Kazemimood R; Davis RE; Jain N; Khoury JD; Sugita M; Cai T; Smith J; Frattini MG; Garton A; Roboz G; Konopleva M
Leuk Res; 2022 Oct; 121():106928. PubMed ID: 35963025
[TBL] [Abstract][Full Text] [Related]
29. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.
Wang S; Wang X; Liu M; Bai O
Ann Hematol; 2018 Apr; 97(4):563-572. PubMed ID: 29455234
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm.
Hwang K; Park CJ; Jang S; Chi HS; Huh JR; Lee JH; Suh C; Lee KH
Histopathology; 2013 Apr; 62(5):764-70. PubMed ID: 23470050
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review.
Wang Y; Xiao L; Yin L; Zhou L; Deng Y; Deng H
Medicine (Baltimore); 2023 Feb; 102(7):e32904. PubMed ID: 36800625
[TBL] [Abstract][Full Text] [Related]
32. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H
Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444
[TBL] [Abstract][Full Text] [Related]
33. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kerr D; Zhang L; Sokol L
Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological analysis of 46 cases with CD4
Suzuki Y; Kato S; Kohno K; Satou A; Eladl AE; Asano N; Kono M; Kato Y; Taniwaki M; Akiyama M; Nakamura S
Histopathology; 2017 Dec; 71(6):972-984. PubMed ID: 28795410
[TBL] [Abstract][Full Text] [Related]
35. Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond.
Pemmaraju N
Curr Hematol Malig Rep; 2017 Dec; 12(6):510-512. PubMed ID: 29064022
[No Abstract] [Full Text] [Related]
36. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP; Rizzieri D; Pemmaraju N
Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
[TBL] [Abstract][Full Text] [Related]
37. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.
Pemmaraju N; Konopleva M
Blood Adv; 2020 Aug; 4(16):4020-4027. PubMed ID: 32841341
[TBL] [Abstract][Full Text] [Related]
38. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
Riaz W; Zhang L; Horna P; Sokol L
Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
[TBL] [Abstract][Full Text] [Related]
39. Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression.
Gulati R; Abu-Salah A; Salous T; Nassiri M
J Hematop; 2022 Mar; 15(1):35-39. PubMed ID: 38358597
[TBL] [Abstract][Full Text] [Related]
40. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]